Basal cochlear lesions result in increased amplitude of otoacoustic emissions

Audiology and Neuro-Otology

Volumn 3, Issue 6, 1998, Pages 361-372

  Kakigi, Akinobu ^a   Hirakawa, Haruo ^a   Harel, Noam ^a   Mount, Richard J ^a   Harrison, Robert V ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Amikacin; Aminoglycoside; Auditory brainstem evoked responses; Cochleogram; Monitoring; Otoacoustic emission; Ototoxicity; Scanning electron microscopy

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE;

AMPLITUDE MODULATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHINCHILLA; COCHLEA INJURY; CONTROLLED STUDY; DEVICE; DISTORTION PRODUCT OTOACOUSTIC EMISSION; ELECTROCOCHLEOGRAPHY; EVOKED OTOACOUSTIC EMISSION; FEMALE; INTRAMUSCULAR DRUG ADMINISTRATION; NONHUMAN; OTOACOUSTIC EMISSION; OTOTOXICITY; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY;

AMIKACIN; ANIMALS; ANTI-BACTERIAL AGENTS; CHINCHILLA; COCHLEA; DIFFERENTIAL THRESHOLD; EAR, INNER; EVOKED POTENTIALS, AUDITORY, BRAIN STEM; FEMALE; MICROSCOPY, ELECTRON, SCANNING; OTOACOUSTIC EMISSIONS, SPONTANEOUS;

EID: 0031786160     PISSN: 14203030     EISSN: None     Source Type: Journal    
DOI: 10.1159/000013806     Document Type: Article

References (28)

1. Sarubbi FA Jr, Hull JH: Amikacin serum concentrations: Prediction of levels and dosage guidelines. Ann Intern Med. 1978;89:612-618.
2. Meyer RD: Amikacin. Ann Intern Med. 1981;95:328-332.
3. Gatell JM, San Miguel JG, Zamora L, Araujo V, Bonet M, Bohe M, Jimenez de Anta MT, Farre M, Elena M, Ballesta A, Marin JL: Comparison of the nephrotoxicity and auditory toxicity of tobramycin and amikacin. Antimicrob Agents Chemother 1983;23:897-901.
4. Barza M, Scheife RT: Antimicrobial spectrum, pharmacology, and therapeutic use of antibiotics. IV. Aminoglycosides. J Maine Med Assoc 1977;68:194-210.
5. Dahlgren JG, Anderson ET, Hewitt WL: Gentamicin blood levels: A guide to nephrotoxicity. Antimicrob Agents Chemother 1975;8:58-62.
6. Plaut ME, Schentag JJ, Jusko WJ: Aminoglycoside nephrotoxicity: Comparative assessment in critically ill patients. J Med. 1979;10: 257-266.
7. Henley CH, Schacht J: Pharmacokinetics of aminoglycoside antibiotics in blood, inner-ear fluids and tissues and their relationship to ototoxicity. Audiology 1988;27:137-146.
8. Hotz MA, Allum JH, Kaufmann G, Follath F, Pfaltz CA: Shifts in auditory brainstem response latencies following plasma-level-controlled aminoglycoside therapy. Eur Arch Otorhinolaryngol 1990;247:202-205.
9. Hawkins JE, Lurie MH: The ototoxicity of dihydrostreptomycin and neomycin in cat. Ann Otol Rhinol Laryngol 1953;62:1128-1148.
10. Lim DJ: Ultrastructural cochlear changes following acoustic hyperstimulation and ototoxicity. Ann Otol Rhinol Laryngol 1976;85:740-751.
11. Hunter-Duvar IM, Mount RJ: The organ of Corti following ototoxic antibiotic treatment. Scanning Electron Microsc 1978;2:423-430.
12. Harrison RV, Evans EF: Cochlear fibre responses in guinea pigs with well defined cochlear lesions. Scand Audiol Suppl 1979;9:83-92.
13. Mountain DC: Electromechanical properties of hair cells; in Altschuler RA, Hoffman DW, Bobbin RP (eds): Neurobiology of Hearing: The Cochlea. New York, Raven Press, 1986, pp 77-90.
14. Brown AM, McDowell B, Forge A: Acoustic distortion products can be used to monitor the effects of chronic gentamicin treatment. Hear Res 1989;42:143-156.
15. Lonsbury-Martin BL, Martin GK, Probst R, Coats AC: Acoustic distortion products in rabbit ear canal. I. Basic features and physiological vulnerability. Hear Res 1987;28:173-189.
16. Martin GK, Lonsbury-Martin BL, Probst R, Scheinin SA, Coats AC: Acoustic distortion products in rabbit ear canal. II. Sites of origin revealed by suppression contours and pure-tone exposures. Hear Res 1987;28:191-208.
17. Zorowka P, Schmitt HJ, Eckel HE, Lippert KL, Schonberger W, Merz E: Serial measurements of transient evoked otoacoustic emissions (TEOAEs) in healthy newborns and in newborns with perinatal infection. Int J Pediatr Otorhinolaryngol 1993;27:245-254.
18. Hotz MA, Harris FP, Probst R: Otoacoustic emissions: An approach for monitoring aminoglycoside-induced ototoxicity. Laryngoscope 1994;104:1130-1134.
19. Henley CM, Rybak LP: Ototoxicity in developing mammals. Brain Res Rev 1995;20:68-90.
20. Henley CM, Weatherly RA, Martin GK, Lonsbury-Martin BL: Sensitive developmental periods for kanamicin ototoxicity effects on distortion-product otoacoustic emissions. Hear Res 1996;98:93-103.
21. Harrison RV, Gordon DC, Nagasawa A, Stanton S, Ibrahim D, Mount RJ: Auditory evoked potentials in cats with neonatal high frequency hearing loss: Evidence of abnormal frequency representation in the midbrain. Acta Otolaryngol Stockh 1993;113:31-38.
22. Bray P, Kemp DT: An advanced cochlear echo technique suitable for infant screening. Br J Audiol 1987; 21:191-204.
23. Kemp DT: Stimulated acoustic emissions from within the human auditory system. J Acoust Soc Am 1978;64:1386-1391.
24. Eldredge DH, Miller JD, Bohne BA: A frequency-position map for the chinchilla cochlea. J Acoust Soc Am 1981;69:1091-1095.
25. Campbell KC, Durrant J: Audiologic monitoring for ototoxicity. Otolaryngol Clin North Am 1993; 26:903-914.
26. Fausti SA, Larson VD, Noffsinger D, Wilson RH, Phillips DS, Fowler CG: High-frequency audiometric monitoring strategies for early detection of ototoxicity. Ear Hear 1994;15:232-239.
27. Brummett RE, Fox KE: Studies of aminoglycoside ototoxicity in animal models; in: Welton A, Neu HC (eds): The Aminoglycosides: Microbiology, Clinical Use, and Toxicology. New York, Dekker, 1982, pp 419-451.
28. Henley CM, Weatherly RA, Martin GK, Lonsbury-Martin BL: Sensitive developmental periods for kanamicin ototoxic effects on distortion-product otoacoustic emissions. Hear Res 1996;98:93-103.